Summary: Two research groups have reported the eŠect of genetic polymorphisms of CYP2C9 and CYP2C19 on the pharmacokinetic parameters of phenytoin in Japanese epileptic patients. We measured the plasma phenytoin concentrations at steady-state in 20 routinely treated Japanese patients, and evaluated the usefulness of genotyping the CYP2C subfamily in predicting plasma concentrations and determining the dosage regimens of phenytoin. The plasma phenytoin concentrations predicted by genotypes of the CYP2C subfamily were well correlated with the observed concentrations in some patients, but not in some patients. The pharmacokinetic parameters (Vmax and Km) in individual patients, which were obtained from population estimates according to Bayes' theorem, showed considerable interindividual variability even among patients with the same genotype. In addition, we assessed the eŠect of plasma protein binding on the residual interindividual variability in the clearance of phenytoin; however, there was no signiˆcant correlation between the unbound fraction and the intrinsic metabolic activity (Vmax W Km). Theseˆndings suggested that the mechanism responsible for the large variability in the clearance of phenytoin is not completely resolved, and that we should not overestimate the usefulness of genotyping the CYP2C subfamily in determining the dosage regimens of the drug.
Introduction
Although phenytoin is widely used in the management of a variety of seizure disorders, there are several complicating factors involved in the dose adjustment of the drug. The therapeutic range of phenytoin is narrow (10-20 mg W mL), and the drug exhibits nonlinear pharmacokinetics with large interindividual diŠerences. 1) Kutt et al. reported on the insu‹cient hydroxylation of phenytoin in a patient who showed intoxication.
2) This insu‹cient metabolism of phenytoin was then suggested to be an inherited defect by pedigree studies. 3) Recently, the genetically polymorphic enzymes, CYP2C9 and CYP2C19, have been shown to be involved in the principal metabolic pathway of phenytoin, namely the formation of 5-(4-hydroxyphenyl)-5-phenylhydantoin. 4, 5) The genetic polymorphism of CYP2C9 was extensively studied, and CYP2C9 * 1 (wild-type) and CYP2C9*3 were identiˆed among Japanese. CYP2C9*3 is an allelic variant in exon 7 which produces an enzyme with an Ile 359 W Leu 359 amino acid substitution, and its frequency among Japanese is reported to be 2.1z. 6) On the other hand, the genetic polymorphism of CYP2C19 was widely observed in Asian populations, and the three polymorphic alleles, CYP2C19*1 (wild-type), CYP2C19*2, and CYP2C19*3 were identiˆed among Japanese.
7) CYP2C19*2 causes a splicing defect in exon 5, and CYP2C19 * 3 creates a premature stop codon in exon 4.
7) The allele frequencies of CYP2C19*2 and CYP2C19*3 among Japanese are reported to be 28.7z and 13.2z, respectively. 8) Odani et al. and Mamiya et al. evaluated the eŠect of genetic polymorphism of the CYP2C subfamily on the pharmacokinetic parameters of phenytoin in Japanese epileptic patients (Table 1) .
9,10) Odani et al. classiˆed 44 patients intoˆve groups based on the patient's genotype of the CYP2C subfamily, and estimated the pharmacokinetic parameters in each group. 9) The maximal elimination rate (Vmax ) of phenytoin is 33z lower in patients heterozygous for CYP2C9*1 W *3 than that in patients homozygous for CYP2C9 * 1 W * 1, and is slightly decreased (up to 14z) in patients with the CYP2C19*2 or CYP2C19*3 allele compared with patients homozygous for CYP2C19 * 1 W * 1. Mamiya et al. reported on the pharmacokinetic parameter set of phenytoin in 134 Japanese patients. 10) A signiˆcant 42z reduction in the Vmax value was estimated in patients heterozygous for CYP2C9*1 W *3, compared with patients homozygous for CYP2C9 * 1 W * 1 ( Table 1) .
In this study, we measured the plasma phenytoin concentrations in 20 routinely treated Japanese patients, and evaluated the usefulness of genotyping the CYP2C subfamily in predicting plasma concentrations and determining the dosage regimens of phenytoin.
Methods
Subjects and study design: The subjects were 20 Japanese patients with epilepsy aged between 2 and 25 (mean±SD: 11.9±5.3) years old. Mean body weight (±SD) was 35.4±13.8 kg, and no patients had severe hepatic or renal failure. These patients were routinely treated with oral administration of phenytoin (Aleviatin } 10z powder, Dainippon Pharmaceutical Co., Osaka, Japan) at Toyama Medical and Pharmaceutical University Hospital. In this study, 4 patients were on monotherapy with phenytoin, whereas 16 patients received other antiepileptic drugs concurrently. Phenytoin was administered three times a day to most patients, and the mean daily dose was 5.19 mg W day W kg. We obtained a total of 121 blood samples at steady-state following repetitive dosing for more than two weeks. The plasma phenytoin concentration was quantiˆed by a ‰uorescence polarization immunoassay (TDX TM , Dainabot, Tokyo, Japan). In addition, the unbound plasma concentrations of phenytoin in 12 patients were measured by an ultraˆltration method.
11) The patients and W or their parents gave written informed consent to participate in this study, which was approved by the ethics committee of Toyama Medical and Pharmaceutical University.
Genotyping procedures for CYP2C9 and CYP2C19: Genomic DNA was isolated from peripheral blood with an extraction kit (Takara, Tokyo, Japan). CYP2C9*1 and CYP2C9 * 3 were determined by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method described by Nasu et al.
6)
CYP2C19*1, CYP2C19*2 and CYP2C19*3 were determined by the PCR-RFLP method described by Lamba et al.
12)
Predictive performance for plasma phenytoin concentration: The plasma phenytoin concentrations in individual patients were predicted according to the pharmacokinetic parameters depicted in Table 1 . In addition, Odani et al. reported that the parameter of power function of weight to adjust the maximal elimination rate (Vmax ) is 0.463, and the Michaelis-Menten constant (Km) of phenytoin is increased 16z by concurrently administered zonisamide.
13) Therefore, we used not only the genotype information of the CYP2C subfamily but also the patient's body weight and the coadministered drug to predict plasma phenytoin concentrations. 9, 10) The predicted drug concentration was compared with the observed (measured) concentrations.
Estimation of pharmacokinetic parameters in individual patients: Mean pharmacokinetic parameters and their interindividual variations in 20 patients were estimated from 121 measured plasma phenytoin concentration data at steady-state (Css ) using the nonlinear mixed eŠects model (NONMEM) program.
14) The pharmacokinetic parameters in individual patients were then obtained from the population estimates according to Bayes' theorem using the NONMEM POSTHOC option. 15) In brief, the plasma phenytoin concentration at steady-state (Css ) was modeled using the following equation:
where Dij and tij are the dose and the dosing interval, respectively, for the j th plasma concentration of the ith patient (Cssij). eij is a random variable describing intraindividual variability with mean zero. Vmaxi is the maximal elimination rate, and Kmi is the MichaelisMenten constant in the ith patient. Vmaxi and Kmi were modeled using the following equations:
where ÃVmax and ÃKm are the population mean values to be estimated, and hVmax i and hKm i are random variables describing interindividual variability of Vmaxi and Kmi with mean zero, respectively. Statistical analysis: Multiple comparison was performed using ScheŠ áe-type test following Kruskal-Wallis analysis. P values of less than 0.05 were considered to be signiˆcantly diŠerent.
Results and Discussion
Our object in this study was to evaluate the usefulness of genotyping of the CYP2C subfamily in predicting plasma phenytoin concentrations and determining the phenytoin dosage regimens. We recruited 20 epileptic patients, and determined their genotypes of the CYP2C subfamily. These patients were divided intoˆve groups according to the genotype of the CYP2C subfamily as reported previously ( Table 1 ). In the present study, Group I consisted ofˆve patients who were homozygous for the wild-type alleles of CYP2C9 and CYP2C19. Seven patients belonged to Group II: three patients were heterozygous for the CYP2C19*1 W *2 alleles, and four patients were heterozygous for the CYP2C19*1 W *3 alleles. Six patients belonged to Group III: one patient was homozygous for the CYP2C19 * 2 allele, three patients were heterozygous for the CYP2C19*2 W *3 alleles, and two patients were homozygous for the CYP2C19*3 allele. No patient belonged to Group IV, which expressed the CYP2C9*1 W *3 and CYP2C19 * 1 W * 1 genotypes. Two patients were heterozygous for the CYP2C9*1 W *3 alleles (Group V): one patient was heterozygous for the CYP2C19*1 W *2 alleles, and the other was heterozygous for the CYP2C19*1 W *3 alleles.
The plasma concentrations predicted according to the reports of Odani et al. 9) and Mamiya et al. 10) were compared with the observed concentrations at steadystate in individual patients (Fig. 1) . In this study, each patient was identiˆed by the group and number. For example, the second patient in Group III was designated as III-2. As shown in Fig. 1 , the correlation between the predicted and observed plasma concentrations was good in some patients (e. g. II-1, III-3, and V-2) . However, the observed plasma concentrations in some patients (e.g. II-6, II-7, and III-6) were signiˆcantly higher than the predicted concentrations. Patient II-6 was a 17-yearold male weighing 49.1 kg who was treated with phenytoin, valproic acid, and carbamazepine. Patient II-7 was a 5-year-old male weighing 16.6 kg who was treated with phenytoin, valproic acid, clobazam, and zonisamide. Patient III-6 was a 14-year-old male weighing 43.9 kg who was treated with phenytoin, valproic acid, and zonisamide. Although Mamiya et al. 10) estimated the pharmacokinetic parameters of phenytoin in 134 Japanese adult patients aged between 18 and 76 years old, Odani et al. 9) estimated the pharmacokinetic parameters of phenytoin in 44 pediatric and adult patients between 1 and 33 years old. In addition, no patients had hepatic or renal failure. In the present study, we used the information about the patient's body weight and coadministered zonisamide to predict plasma phenytoin concentration as describe in the Method section, and none of the three patients (II-6, II-7, and III-6) had received any other potent inhibitors of CYP2C9 and CYP2C19 (e.g. omeprazole, ticlopidine). Accordingly, we could not explain the reduced clearance of phenytoin by the patient's age, physical diagnosis, and coadministered drug in these three patients.
We estimated the pharmacokinetic parameters of phenytoin in individual patients according to Bayes' theorem in order to evaluate the eŠect of genotypes of the CYP2C subfamily on the pharmacokinetics and to estimate its interindividual variability. As shown in Fig. 2 , the in‰uences of genotype of the CYP2C subfamily on Vmax and Vmax W Km were observed, though this was not statistically signiˆcant (0.05ºPº0.1, Kruskal-Wallis analysis). However, it was clear that there is a large interindividual variation in the pharmacokinetic parameters (Vmax, Km, and Vmax W Km) even among patients with the same genotype (Fig. 2) . The coe‹cient of variation in the intrinsic clearance (Vmax W Km) for Group I, II, and III was estimated to be 19.0z, 23.8z, and 21.2z, respectively (Fig. 2C) .
The unbound fraction of phenytoin is known to show large interindividual diŠerences among patients, and an increased unbound fraction would result in a proportional increase in metabolic drug clearance. 11, 17) In this study, therefore, we evaluated the plasma unbound fraction of phenytoin in 12 patients. Figure 3 shows the relationship between the intrinsic metabolic activity (Vmax W Km) and the plasma unbound fraction of phenytoin in 12 patients who belonged to Group 1, Group 2, or Group 3. The unbound fraction of phenytoin showed considerable interindividual variability in each genotype group; however, there was no positive correlation between the unbound fraction and Vmax W Km (Fig. 3) . This suggested that the unbound fraction of phenytoin was unlikely to be responsible for the large interindividual variability of the pharmacokinetics of phenytoin. This observation may be consistent with that of Yacobi et al., 18) who reported that protein binding is not a cause of the pronounced interindividual diŠerences in phenytoin clearance of subjects with normal renal function. Theˆndings in this study indicated that the genetic polymorphism of the CYP2C subfamily is the major Fig. 3 . Correlation between Vmax W Km and the plasma unbound fraction of phenytoin in 12 patients in three genotype groups. Group I, CYP2C19 * 1 W * 1; Group II, CYP2C19 * 1 W * 2 or * 1 W * 3; Group III, CYP2C19 * 2 W * 2 or * 2 W * 3. Circles correspond to individual estimates andˆgures mean patient number. factor aŠecting the pharmacokinetics of phenytoin, but that the mechanism responsible for the large variability in the clearance of phenytoin is not completely resolved. Therefore, we should not overestimate the usefulness of genotyping the CYP2C subfamily in determining the phenytoin dosage regimens, and should monitor the plasma (unbound) concentrations of phenytoin when treating epileptic patients.
